H5N1 influenza is evolving rapidly, weakening the effectiveness of existing antibodies and increasing its potential threat to ...

Researchers have identified antibodies that could lead to a broadly protective norovirus vaccine and new treatment options.

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...

Kairos Pharma (NYSE American: KAPA) , a clinical-stage biopharmaceutical company, has published a peer-reviewed study highlighting a potential breakt ...

A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a vaccine or pathogen, B cells scramble to refine their defenses, rapidly mutating ...

The H5N1 influenza virus poses a significant threat to public health due to its potential to shift from an epidemic to a pandemic. Since its emergence in the 1990s, H5N1 has demonstrated a concerning ...

PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 ...

The chikungunya virus virus-like particle vaccine is well tolerated and shows high immunogenicity in both previous recipients ...

Researchers evaluated the potential clinical impact and cost-effectiveness of administering long-acting, injectable ...

Taimed Biologics Inc.’s TMB-365/TMB-380 long-acting combination of broadly neutralizing antibodies (bnAbs) regimen for HIV maintenance could reshape HIV treatment management, offering a viable ...

A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a vaccine or pathogen, B cells scramble to refine their defenses, rapidly mutating ...

A main obstacle to an HIV cure is that viral DNA integrates into the chromosomes of memory T cells (blue), which evade ...